26.96% -0.55

Handel nachbörslich: 1.40 -0.09 -6.04%

Theriva Biologics Inc (TOVX)

Theriva Biologics Inc Aktie (TOVX) Neueste Nachrichten

Theriva Biologics Inc (TOVX)

Theriva Biologics Inc Aktie (TOVX) Neueste Nachrichten

Theriva Biologics Announces Pricing of $2.5 Million Public Offering - StockTitan

Theriva Biologics Announces Pricing of $2.5 Million Public Offering - GlobeNewswire

Theriva Biologics Inc (TOVX) Stock: From Low to High in 52 Weeks - The InvestChronicle

Understanding TOVX stock ratios for better investment decisions - US Post News

Synthetic Biologics stock plunges to 52-week low of $2.66 - Investing.com

Telesis Bio Inc (TBIO) Stock: 52-Week Performance Insights and Trading Volume - The InvestChronicle

TRxADE Health rebrands as Scienture Holdings with new ticker SCNX - Investing.com

An Analysis of Theravance Biopharma Inc (TBPH)’s Potential Price Growth - Knox Daily

Market Recap: Trupanion Inc (TRUP)’s Positive Momentum, Closing at 42.80 - The Dwinnex

Interval Partners LP Makes New $10.41 Million Investment in TransDigm Group Incorporated (NYSE:TDG) - Defense World

Investing in Hercules Capital Inc (HTGC): What You Must Know - Knox Daily

Morse Asset Management Inc Invests $701,000 in Hercules Capital, Inc. (NYSE:HTGC) - MarketBeat

Theriva Biologics Advances VCN-01 in VIRAGE Phase 2b Trial - TipRanks

Theriva™ Biologics Achieves Target Patient Enrollment in - GlobeNewswire

Theriva™ Biologics Achieves Target Patient Enrollment in the VIRAGE Phase 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer - StockTitan

Thryv Holdings, Inc. (NASDAQ:THRY) Shares Acquired by Harspring Capital Management LLC - Defense World

Harspring Capital Management LLC Purchases 30,000 Shares of Thryv Holdings, Inc. (NASDAQ:THRY) - MarketBeat

Hancock Whitney Corp Cuts Position in Tenet Healthcare Co. (NYSE:THC) - Defense World

Inspire Investing LLC Reduces Stock Holdings in Hercules Capital, Inc. (NYSE:HTGC) - Defense World

35,000 Shares in Trupanion, Inc. (NASDAQ:TRUP) Purchased by Dalton Investments Inc. - MarketBeat

Blair William & Co. IL Raises Stake in Thryv Holdings, Inc. (NASDAQ:THRY) - Defense World

Victory Capital Management Inc. Has $758,000 Holdings in Thryv Holdings, Inc. (NASDAQ:THRY) - Defense World

Huber Capital Management LLC Trims Holdings in Tenet Healthcare Co. (NYSE:THC) - Defense World

Trupanion (NASDAQ:TRUP) Given New $45.00 Price Target at Northland Securities - Defense World

Texas Permanent School Fund Corp Has $1.08 Million Stake in Trupanion, Inc. (NASDAQ:TRUP) - Defense World

Rhumbline Advisers Lowers Position in Thryv Holdings, Inc. (NASDAQ:THRY) - Defense World

Renaissance Technologies LLC Takes Position in Tenet Healthcare Co. (NYSE:THC) - Defense World

Trupanion (NASDAQ:TRUP) Shares Gap Up on Analyst Upgrade - MarketBeat

Traws Pharma Announces Key Approvals and Reverse Stock Split at 2024 Special Meeting - MyChesCo

Tenet Healthcare stock hits 52-week high at $166.9 amid robust growth - Investing.com

Choreo LLC Invests $335,000 in Tenet Healthcare Co. (NYSE:THC) - Defense World

Theriva Biologics Secures Funding for Viral Therapy Innovation - TipRanks

Theriva™ Biologics Awarded Manufacturing Funding from the Spanish Government’s National Knowledge Transfer Program - StockTitan

Theriva™ Biologics Awarded Manufacturing Funding from the - GlobeNewswire

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) Short Interest Update - Defense World

Theriva Biologics announces preferred stock conversion By Investing.com - Investing.com Australia

Theriva Biologics announces preferred stock conversion - Investing.com India

Theriva Biologics announces preferred stock conversion - Investing.com

TOVX’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle

Daily Market Movement: Theriva Biologics Inc (TOVX) Sees a 35.71 Increase, Closing at 4.37 - The Dwinnex

Synthetic Biologics (SYN) Stock Price, News & Analysis - MarketBeat

A stock that deserves closer examination: Theriva Biologics Inc (TOVX) - US Post News

Theriva Biologics (TOVX) Is Making Noise With a Promising Pipeline - Nasdaq

Theriva Biologics Inc (TOVX) Stock: A Comprehensive 52-Week Review - The InvestChronicle

What's Going On With Theriva Biologics Stock? - MSN

Theriva Biologics Inc (TOVX) Stock: 52-Week Performance Insights and Trading Volume - The InvestChronicle

What's Going On With Theriva Biologics Stock? - Benzinga

Holdings of Theriva Biologics Inc (TOVX) are aligned with the stars - SETE News

Daily Market Movement: Theriva Biologics Inc (TOVX) Sees a 34.29 Increase, Closing at 4.70 - The Dwinnex

Why Affirm Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Benzinga

Synthetic Biologics Inc announced that it has received $10.80 million in funding. - Marketscreener.com

SYNTHETIC BIOLOGICS, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) - Marketscreener.com

Theriva Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 - Marketscreener.com

Synthetic Biologics Inc. Appoints Raymond Stapleton as Senior Vice President of Manufacturing - Marketscreener.com

Isaac J. Bright Joins Synthetic Biologics as Vice President, Corporate Development - Marketscreener.com

Synthetic Biologics Appoints Deb Mathews as Vice President, Medical Affairs - Marketscreener.com

Theriva Biologics Announces Key Progress in Virage, an Ongoing, Multinational Phase 2B Trial of VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma - Marketscreener.com

Synthetic Biologics, Inc. Appoints Steven A. Shallcross as Chief Executive Officer and Director - Marketscreener.com

Synthetic Biologics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021 - Marketscreener.com

Theriva Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 - Marketscreener.com

Theriva Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma - Marketscreener.com

Theriva Biologics, Inc. Receives Rare Pediatric Drug Designation by the U.S. FDA for VCN-01 for the Treatment of Retinoblastoma - Marketscreener.com

Theriva Biologics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 - Marketscreener.com

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) Sees Significant Decline in Short Interest - MarketBeat

Theriva Biologics Inc (TOVX) Stock: Uncovering 52-Week Market Trends - The InvestChronicle

Is it possible to buy Theriva Biologics Inc(TOVX) shares at a good price now? - US Post News

Theriva Biologics executes reverse stock split - Investing.com

Theriva Biologics executes reverse stock split By Investing.com - Investing.com UK

Theriva Biologics (NYSEAMERICAN:TOVX) Shares Scheduled to Reverse Split on Monday, August 26th - Defense World

A new trading data show Theriva Biologics Inc (TOVX) is showing positive returns. - SETE News

TOVX Stock Earnings: Theriva Biologics Beats EPS for Q2 2024 - MSN

Ähnlich wie TOVX